These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24780597)

  • 1. Synthesis of 5-substituted-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one analogs and their biological evaluation as anticancer agents: mTOR inhibitors.
    Reddy GL; Guru SK; Srinivas M; Pathania AS; Mahajan P; Nargotra A; Bhushan S; Vishwakarma RA; Sawant SD
    Eur J Med Chem; 2014 Jun; 80():201-8. PubMed ID: 24780597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as dual PI3Kα/mTOR inhibitors.
    Lei F; Sun C; Xu S; Wang Q; OuYang Y; Chen C; Xia H; Wang L; Zheng P; Zhu W
    Eur J Med Chem; 2016 Jun; 116():27-35. PubMed ID: 27043268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
    Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
    J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors.
    Saurat T; Buron F; Rodrigues N; de Tauzia ML; Colliandre L; Bourg S; Bonnet P; Guillaumet G; Akssira M; Corlu A; Guillouzo C; Berthier P; Rio P; Jourdan ML; Bénédetti H; Routier S
    J Med Chem; 2014 Feb; 57(3):613-31. PubMed ID: 24345273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel pyrazolo[3,4-d]pyrimidine with 4-(1H-benzimidazol-2-yl)-phenylamine as broad spectrum anticancer agents: Synthesis, cell based assay, topoisomerase inhibition, DNA intercalation and bovine serum albumin studies.
    Singla P; Luxami V; Singh R; Tandon V; Paul K
    Eur J Med Chem; 2017 Jan; 126():24-35. PubMed ID: 27744184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, anticancer and radioprotective activities of some new pyrazolo[3,4-d]pyrimidines containing amino acid moieties.
    Ghorab MM; Ragab FA; Noaman E; Heiba HI; Aboulmagd SA
    Arzneimittelforschung; 2009; 59(2):96-103. PubMed ID: 19338140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
    Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
    J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antiproliferative activity in vitro of new 2-, 3- or 4-substituted pyrido[2',3':3,4]pyrazolo[1, 5-a]pyrimidines.
    Poreba K; Wietrzyk J; Opolski A
    Acta Pol Pharm; 2006; 63(3):189-94. PubMed ID: 20085223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
    Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
    Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
    Lee W; Ortwine DF; Bergeron P; Lau K; Lin L; Malek S; Nonomiya J; Pei Z; Robarge KD; Schmidt S; Sideris S; Lyssikatos JP
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5097-104. PubMed ID: 23932790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of pyrazolo[3,4-d]pyrimidin-4(5H)-ones tethered to 1,2,3-triazoles and their evaluation as potential anticancer agents.
    Allam M; Bhavani AKD; Mudiraj A; Ranjan N; Thippana M; Babu PP
    Eur J Med Chem; 2018 Aug; 156():43-52. PubMed ID: 30006173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors.
    Zhu W; Sun C; Xu S; Wu C; Wu J; Xu M; Zhao H; Chen L; Zeng W; Zheng P
    Bioorg Med Chem; 2014 Dec; 22(24):6746-54. PubMed ID: 25468038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
    Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P
    Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facile synthesis and antiproliferative activity of 7H-benzo[7,8]chromeno[2,3-d]pyrimidin-8-amines.
    Akrami H; Safavi M; Mirjalili BF; Dehghani Ashkezari M; Dadfar F; Mohaghegh N; Emami S; Salehi F; Nadri H; Ardestani SK; Firoozpour L; Khoobi M; Foroumadi A
    Eur J Med Chem; 2017 Feb; 127():128-136. PubMed ID: 28039771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones.
    Lamie PF
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3093-3097. PubMed ID: 27189674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some pyrazole and pyrazolo[3,4-d]pyrimidine derivatives: synthesis and anticancer evaluation.
    Shamroukh AH; Rashad AE; Abdel-Megeid RE; Ali HS; Ali MM
    Arch Pharm (Weinheim); 2014 Aug; 347(8):559-65. PubMed ID: 24801813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and anticancer evaluation of novel pyrazole, pyrazolo[3,4-d]pyrimidine and their glycoside derivatives.
    Nassar IF; El Farargy AF; Abdelrazek FM; Ismail NSM
    Nucleosides Nucleotides Nucleic Acids; 2017 Apr; 36(4):275-291. PubMed ID: 28323527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors.
    Al-Ashmawy AAK; Ragab FA; Elokely KM; Anwar MM; Perez-Leal O; Rico MC; Gordon J; Bichenkov E; Mateo G; Kassem EMM; Hegazy GH; Abou-Gharbia M; Childers W
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3117-3122. PubMed ID: 28571824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-(N-Phenyl-N'-substituted benzenesulfonyl)-6-(4-hydroxyphenyl)quinolines as inhibitors of mammalian target of rapamycin.
    Venkateswarlu V; Pathania AS; Aravinda Kumar KA; Mahajan P; Nargotra A; Vishwakarma RA; Malik FA; Sawant SD
    Bioorg Med Chem; 2015 Aug; 23(15):4237-4247. PubMed ID: 26162498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors.
    Lv X; Ying H; Ma X; Qiu N; Wu P; Yang B; Hu Y
    Eur J Med Chem; 2015 Jun; 99():36-50. PubMed ID: 26046312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.